ORGO Organogenesis Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661181 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.3%
TTM net income YoY-13,567.9%
TTM EPS YoY-1,400.0%
Revenue 3-yr CAGR-7.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-24.5%
Net margin-38.4%
FCF margin-0.0%
EBITDA margin-20.0%
Returns
ROE-72.2%
ROA-30.8%
ROIC (approx.)-47.0%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets28.8%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.08x
Accruals ratio-33.2%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $45.46M | $43.76M | $37.23M | $225.61M | $150.86M | $101.00M | $86.69M | $126.66M |
| Cost of revenue | — | — | — | — | — | — | $23.72M | $31.05M |
| Gross profit | — | — | — | — | — | — | $62.97M | $95.61M |
| R&D expense | $7.96M | $18.30M | $15.16M | $10.29M | $13.22M | $10.39M | $10.64M | $11.53M |
| SG&A expense | $45.09M | $53.97M | $65.19M | $100.17M | $79.74M | $73.81M | $72.51M | $73.86M |
| Operating income | -$29.49M | -$50.99M | -$68.89M | $63.29M | $20.73M | -$12.58M | -$26.75M | $10.22M |
| Interest expense | — | -$138,000 | -$380,000 | -$236,000 | -$415,000 | -$669,000 | -$961,000 | -$61,000 |
| Pretax income | -$29.62M | -$50.88M | -$68.47M | $63.43M | $21.16M | -$11.83M | -$25.78M | $10.25M |
| Income tax | $8,000 | $45.39M | -$15.32M | $19.73M | -$407,000 | -$2.44M | -$6.94M | $2.58M |
| Net income | -$29.63M | -$96.27M | -$53.16M | $43.70M | $21.57M | -$9.39M | -$18.84M | $7.67M |
| EBITDA | -$25.56M | -$47.32M | -$64.72M | $67.36M | $24.76M | -$8.84M | -$23.30M | $13.83M |
| EPS (basic) | -0.25 | -0.77 | -0.44 | — | 0.11 | -0.10 | -0.17 | — |
| EPS (diluted) | -0.25 | -0.77 | -0.44 | — | 0.11 | -0.10 | -0.17 | — |
| Weighted avg. shares (diluted) | 128.99M | 128.67M | 127.80M | — | 130.85M | 126.85M | 126.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $21.33M | $46.10M | $91.38M | $93.68M | $64.37M | $73.73M | $110.53M | $136.15M |
| Receivables | $92.69M | $100.94M | $116.91M | $217.45M | $168.78M | $120.38M | $103.32M | $109.86M |
| Inventory | $26.68M | $29.28M | $28.43M | $29.63M | $39.58M | $33.04M | $29.34M | $26.22M |
| Current assets | $158.13M | $200.30M | $268.50M | $362.19M | $299.75M | $260.22M | $268.16M | $285.94M |
| PP&E, net | $98.60M | $101.53M | $104.08M | $103.71M | $78.06M | $75.61M | $75.52M | $89.13M |
| Goodwill | $28.77M | $28.77M | $28.77M | $28.77M | $28.77M | $28.77M | $28.77M | $28.77M |
| Intangibles | $2.57M | $3.00M | $3.44M | $9.14M | $9.94M | $10.79M | $11.63M | $12.47M |
| Total assets | $368.90M | $406.45M | $519.99M | $598.73M | $509.83M | $461.13M | $467.39M | $497.89M |
| Current liabilities | $47.65M | $56.96M | $76.02M | $100.12M | $90.32M | $65.84M | $65.05M | $77.48M |
| Total liabilities | $106.16M | $118.31M | $138.65M | $164.81M | $123.85M | $99.91M | $99.33M | $112.57M |
| Shareholders' equity | $119.74M | $148.27M | $244.56M | $300.13M | $255.13M | $233.24M | $242.90M | $262.90M |
| Shares outstanding | 129.79M | 128.67M | 128.67M | 126.95M | 126.91M | 126.85M | 126.85M | 125.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.59M | -$31.65M | $21.13M | $39.42M | $3.08M | -$32.87M | -$19.93M | $10.94M |
| Capital expenditure | $1.47M | $1.10M | $3.15M | $4.65M | $2.23M | $3.64M | $3.63M | $3.36M |
| Free cash flow | -$20.06M | -$32.75M | $17.98M | $34.77M | $844,000 | -$36.51M | -$23.56M | $7.58M |
| Investing cash flow | $2.15M | -$1.10M | -$3.15M | -$4.65M | -$2.23M | -$3.64M | -$3.63M | -$3.36M |
| Financing cash flow | -$3.46M | -$12.50M | -$20.21M | -$4.81M | -$10.21M | -$288,000 | -$2.06M | $33.65M |
| Depreciation & amortization | $3.93M | $3.67M | $4.17M | $4.07M | $4.03M | $3.73M | $3.44M | $3.62M |
| Stock-based compensation | $2.81M | $3.05M | $3.64M | $4.32M | $3.06M | $2.54M | $3.37M | $2.89M |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.